TLCD3B

Across TCGA pan-cancer cohorts, TLCD3B RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TLCD3B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where TLCD3B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TLCD3B is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

KIRP, LIHC, and KIRC are the cancer types where TLCD3B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TLCD3B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	III,IV	+0.366	<.001	11	view →
LIHC	All	All	+0.163	<.001	8	view →
KIRC	Male	All	+0.159	<.001	8	view →
THCA	All	All	+0.099	<.001	8	view →
BRCA	All	III,IV	+0.945	<.001	6	view →
HNSC	Male	All	−0.651	.006	5	view →
LUAD	Female	All	+0.161	<.001	5	view →
LUSC	All	All	+0.250	<.001	4	view →
CHOL	All	All	+0.150	.016	4	view →
STAD	Male	II,III,IV	+0.144	.005	4	view →
UCEC	All	All	+0.227	.003	2	view →
BLCA	Female	All	+0.132	.020	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TLCD3B–KIRP

Open the KIRP breakdown →